- Samsung Biologics has signed a 1.8 trillion won ($1.3 billion) contract with a US pharmaceutical company, its second-largest deal since inception.
- The agreement extends through 2029 and pushes the company’s cumulative orders since 2011 beyond $20 billion.
Samsung Biologics announced it has clinched a 1.8 trillion won ($1.3 billion) contract with a US pharmaceutical company, marking its second-biggest deal since the company was founded in 2011. The Incheon-based contract drug manufacturer disclosed the agreement in a filing on Tuesday.
The contract, which runs through 2029, lifts Samsung Biologics’ order tally for the year to 5.2 trillion won. This nearly matches the company’s entire 2024 total within the first eight months of 2025. Cumulative orders now exceed $20 billion since its establishment.
Under confidentiality terms, the name of the client and details of the product remain undisclosed. The deal follows a $1.4 billion contract manufacturing organisation (CMO) agreement signed with an unidentified European pharmaceutical company in January, highlighting two large-scale wins in under a year.
The new agreement comes amid uncertainty in global trade conditions. While the Trump administration recently agreed to cap tariffs at about 15% on imports from South Korea, Japan, the UK and the EU, a formal deal has yet to be finalised. This leaves South Korean pharmaceutical and biotech companies, including Samsung Biologics, exposed to the possibility of higher US duties.
